Psychedelic News

Bipartisan Congressional Lawmakers Tell DEA To Allow Psilocybin Treatment For Terminal Patients
Bipartisan members of Congress sent a letter requesting that the Drug Enforcement Administration (DEA) allow terminally ill patients to use psilocybin as an investigational treatment without the fear of federal prosecution.
Published: 2022-01-18
Type: Regulatory
Optimi Health Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations for Provisional Patent
Optimi Health Corp. has announced a second provisional patent for a proprietary two-part processing method that involves the extraction and transdermal delivery of psilocybin active components.
Published: 2022-01-18
Type: Press Release
Rollups: The Emerging Magic Mushroom Monopoly
Luke Goldstein at The American Prospect explores the commercialization of psilocybin mushroom as part of their Rollups series.
Published: 2022-01-10
Type: Popular Press
A Psychedelic May Soon Go to the FDA for Approval to Treat Trauma
Jennifer Mithcell at Scientific America explores how MDMA is being used to treat PTSD.
Published: 2022-01-20
Type: Scientific / Research
Psygen Receives Dealer's Licence from Health Canada
Psygen Industries Ltd. is pleased to announce that its wholly-owned subsidiary, Psygen Labs Inc., received a dealer’s licence issued by Health Canada on January 17, 2022. Upon completion of its facility in Calgary, Psygen will begin onsite manufacturing of synthetic psychedelics in accordance with Good Manufacturing Practices (GMP) for use in clinical and scientific research.
Published: 2022-01-17
Type: Press Release
Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial
Numinus Wellness Inc. has announced that it has completed key steps to prepare to enrol participants at its clinics participating in “A multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD (MAPPUSX)”, sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS).
Published: 2022-01-19
Type: Press Release
Awakn Life Sciences Signs MOU with MAPS
Awakn Life Sciences Corp. has announced that it has signed a Memorandum of Understanding with the Multidisciplinary Association for Psychedelic Studies (MAPS) to explore a partnership to utilize MDMA-assisted therapy to treat Alcohol Use Disorder (AUD) in Europe.
Published: 2022-01-19
Type: Press Release
Two-thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression
COMPASS Pathways has announced the findings from a survey of Sermo physician members that showed two thirds (66%) of doctors surveyed believe psilocybin therapy has potential therapeutic benefit for patients with treatment-resistant depression (TRD).
Published: 2022-01-19
Type: Healthcare
British Psychedelic Drug Firm Eleusis Plans $450 Million SPAC Deal
Eleusis is going public through a merger with a blank-check firm, according to people with knowledge of the matter. The U.K.-based company will combine with Silver Spike Acquisition Corp. II in a deal that values Eleusis at about $450 million.
Published: 2022-01-20
Type: Investment
MindMed Enrolls First Participant in a Study of its Session Monitoring System
Mind Medicine (MindMed) Inc has announced that it has enrolled the first subjects into its Session Monitoring System (SMS-01) study evaluating the passive collection of sensory data during a consciousness-altering therapeutic session. SMS-01 utilizes MindMed’s Session Monitoring System (MSMS), which it believes could have therapeutic applications in the treatment of psychiatric disorders.
Published: 2022-01-18
Type: Press Release
Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada's Special Access Program
Mydecine Innovations Group has announced it has signed a Letter of Intent (LOI) with The Newly Institute Inc. (“The Newly”), a Calgary, Alberta based company opening private inter-disciplinary mental health clinics across Canada, to collaborate on expanding psychedelic-assisted psychotherapy to patients.
Published: 2022-01-18
Type: Press Release
Numinus seeks Health Canada approval to start psychedelic product trial
Numinus Wellness has announced the submission of the clinical trial application (CTA) to Health Canada to commence the Phase I clinical trial of a naturally derived Psilocybe extract formulation, NBIO-01, for psychedelic-assisted therapies.
Published: 2022-01-17
Type: Scientific / Research
Wesana Health Granted US FDA Pre-IND Meeting for SANA-013
Wesana Health has announced that the U.S Food and Drug Administration (U.S. FDA) granted the Company’s request for a pre-IND (Investigational New Drug) meeting to discuss the novel therapy and proprietary protocol of SANA-013 for the treatment of Traumatic Brain Injury (TBI) related major depressive disorder (MDD).
Published: 2022-01-11
Type: Press Release
Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain
Cybin Inc. has announced that an Institutional Review Board has approved a Company-sponsored feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow, to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics.
Published: 2022-01-11
Type: Press Release
PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS
PharmaTher has announced that the U.S. Food and Drug Administration (“FDA”) has accepted an investigator-initiated investigational new drug (“IND”) application to proceed with a Phase 2 clinical trial (the “Study”) evaluating ketamine in the treatment of Amyotrophic Lateral Sclerosis (“ALS”), also known as Lou Gehrig’s disease. The Study will be conducted at the University of ...

Read more

Published: 2022-01-12
Type: Press Release
Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development
Field Trip Health has announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Field Trip’s patent application No. 17/364,047 for claims related to FT-104 (informally known as “Isoprocin Glutarate”), Field Trip’s first novel psychedelic molecule in development. Claims in the allowed patent application titled, “Tryptamine Prodrugs”, cover composition ...

Read more

Published: 2022-01-11
Type: Press Release
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program
atai Life Sciences have announced that the U.S. Food and Drug Administration (FDA) has given Investigational New Drug (IND) clearance to conduct a clinical DDI study of PCN-101 (R-ketamine). atai plans to initiate the study early this year through its platform company Perception Neuroscience.
Published: 2022-01-12
Type: Press Release
Psychedelic beer served at intimate dinner parties helped an ancient empire in the Andes rule for centuries, study finds
A new archaeological study adds to the rich history of psychedelics in South America. Archaeologists found vilca seeds at a site in Southern Peru which they believe were added beer at feasts to help Wari leaders, who ruled in Peru over 1,400 years ago, reinforce their power and build a sense of community.
Published: 2022-01-16
Type: Popular Press
Top Federal Drug Official Says ‘Train Has Left The Station’ On Psychedelics As Reform Movement Spreads
National Institute on Drug Abuse (NIDA) Director Nora Volkow says the “train has left the station” on psychedelics. In light of the recent workshop on psychedelics hosted by the NIH, Ms. Volkow stated that people are going to keep using substances such as psilocybin—especially as the reform movement expands and there’s increased attention being drawn ...

Read more

Published: 2022-01-17
Type: Popular Press
Sydney Researchers Awarded Over $2.2 Million By Australian Government To Study MDMA, Psilocybin
Researchers at the University of Syndey have been awarded over $2.2M to study MDMA-assisted therapy to treat combined post-traumatic stress disorder (PTSD) and alcohol use disorder, as well as a clinical trial of psilocybin-assisted psychotherapy in anorexia nervosa.
Published: 2022-01-18
Type: Popular Press
PsyMed Ventures, our $25M fund to invest in psychedelic medicine & mental health tech
The hosts of the Business Trip podcast have started a $25M fund with Dina Burkitbayeva to invest in psychedelic medicine companies and mental health technologies: PsyMed Ventures.
Published: 2022-01-10
Type: Investment
Canada Opens New Legal Pathways For Access To Psychedelics Treatment With Psilocybin And MDMA
An amendment to federal regulations will allow physicians in Canada to request access to drugs like psilocybin and MDMA through the Special Access Program. A major win for the therapeutic potential of psychedelics.
Published: 2022-01-05
Type: Regulatory
Psilocybin Services Would Be Legalized In Washington State Under New Bill
A new bill introduced by lawmakers in Washington State would establish a legal, regulated psilocybin industry available to all adults 21 years and older regardless of mental health status.
Published: 2022-01-06
Type: Popular Press
New Filing Challenges Compass Pathways’ Infamous Patent on Synthetic Psilocybin
Psychedelic reporter Shayla Love explores the implications of a recent publication on the crystalline structures of psilocybin has for patents within the psychedelic industry.
Published: 2021-12-15
Type: Popular Press
Ketamine therapy swiftly reduces depression and suicidal thoughts
Ketamine therapy has a swift short-term effect on reducing symptoms of depression and suicidal thoughts, according to a review of all the available evidence.
Published: 2021-12-23
Type: Press Release
Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder (TRYPF)
Tryp Therapeutics announced today the receipt of correspondence from the U.S. Food and Drug Administration (FDA) affirming the Company’s ability to proceed with a Phase 2a clinical trial evaluating the use of synthetic psilocybin for binge eating disorder.
Published: 2021-12-23
Type: Press Release
Cybin Earns Notice Of Allowance For CYB004
Cybin (CYBN) was recently awarded a Notice of Allowance for it CYB004 deuterated psychedelic tryptamine used to treat anxiety disorders.
Published: 2021-12-21
Type: Press Release
Entheon Biomedical Corp
Entheon Biomedical Corp. announced that its expanded psychedelics genetic testing panel, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc., is now available for sale in Canada and the United States.
Published: 2021-12-21
Type: Press Release
Mydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Therapeutic Platform Aiming to Further Increase Safety, Efficacy, and Accessibility of Psychedelic-Assisted Treatments
Mydecine Innovations Group, a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, announced today that the Company has signed an LOI with Maya.
Published: 2021-12-22
Type: Press Release
MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder
Mind Medicine (MindMed) Inc. today announced that the U.S. Food and Drug Administration has placed a clinical hold on its IND submission intended to support the initiation of a Phase 2b trial of lysergic acid diethylamide (LSD) for the treatment of generalized anxiety disorder (GAD).
Published: 2021-12-21
Type: Press Release

Find Psychedelic News Articles

Discover the latest news articles published on psychedelics with a focus on psychedelics as medicine. We cover all popular press, press releases, notable articles, and blogs on psychedelics.

Read the full articles on the individual websites, press releases on Blossom, and our quick take directly in the summary.

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account